Systemic treatment policies in ovarian cancer: The next 10 years

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 231-240

  Biagi, James J ^a   Eisenhauer, E A ^b  

^a Cancer Centre of South Eastern Ontario   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Evidence based medicine; Ovarian cancer; Review; Systemic therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 7 HYDROXYSTAUROSPORINE; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN 1; CANERTINIB; CARBOPLATIN; CETUXIMAB; CGP 69846A; CISPLATIN; COMBRETASTATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ENDOSTATIN; EPIRUBICIN; ERLOTINIB; GEFITINIB; IMATINIB; ISIS 2503; LONAFARNIB; N ACETYLCOLCHINOL PHOSPHATE; OREGOVOMAB; PACLITAXEL; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ALOPECIA; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; POLICY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANADA; CARBOPLATIN; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PRACTICE GUIDELINES;

EID: 1242275074     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13356.x     Document Type: Conference Paper

References (42)

1. Browman GP, Levine MN, Mohide EA et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
2. Omura GA, Buyse M, Morsoni S et al. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991;9:1668-74.
3. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479-87.
4. Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002;85:71-80.
5. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
6. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
7. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000;18:106-15.
8. Parmar MKB, Adams M, Balestrino M et al. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
9. Parmer MKB, Torri V, Bonaventika A et al. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:1571-6.
10. du Bois A, Weber B, Pfisterer J et al. Epirubicin/paclitaxel/carboplatin (TEC) Vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim Results of an AGO-GINECO Intergroup Phase III Trial. Proc Am Soc Clin Oncol 2001;20:202a [Abstract].
11. Aabo K, Adams M, Adnitt P et al. Advanced Ovarian Cancer Trialists G. Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews 2002.
12. Conte PF, Bruzzone M, Carnino F et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 1996;14:351-6.
13. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996;14:2113-9.
14. Ngan HY, Choo YC, Cheung M et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 1989;35:221-7.
15. Gore M, Mainwaring P, A'Hern R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998;16:2426-34.
16. Dittrich C, Obermair A, Kurz C et al. Prospective randomized trial of cisplatin/carboplatin versus conventional cisplatin/cyclophosphamide in epithelial ovarian cancer: first results of the impact of platinum dose intensity on patient outcome. Proc Am Soc Clin Oncol 1996; 15:279 [Abstract].
17. Jakobsen A, Bertelsen K, Andersen JE et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 1997;15:193-8.
18. Bella M, Cocconi G, Lottici R et al. Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann Oncol 1994;5:23 [Abstract].
19. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
20. Ehrlich CE, Einhorn L, Stehman FB, Blessing J. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan - the Indiana University experience. Clin Obstet Gynaecol 1983;10:325-35.
21. Colombo N, Pittelli M, Parma G et al. Cisplatin dose intensity in advanced ovarian cancer: A randomized study of dose-intense versus standard-dose cisplatin monochemotherapy. Proc Am Soc Clin Oncol 1993;12:255 [Abstract].
22. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997;8:327-33.
23. Joly F, Heron JF, Kerbrat P et al. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol 2000;78:361-8.
24. Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC). Preliminary results of a GINECO/ FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2001;20:204a [Abstract].
25. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998;55:5-30.
26. Ozols R, Bundy B, Fowler J et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A gynecologic oncology group trial (GOG 158). Proc Am Soc Clin Oncol 1999;18:356a. [Abstract].
27. du Bois A, Lueck H, Meier W et al. Cisplatin/paclitaxel Vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol 1999;18:356a [Abstract].
28. Neijt JP, Engelholm SA, Tuxen MK et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
29. Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002;87:815-24.
30. Vasey P. Preliminary results of SCOTROC 2A, a randomised feasibility study of carboplatin (C) then sequential docetaxel (D) or two schedules of docetaxel + gemcitabine (G) in ovarian/mullerian cancers. Proc Am Soc Clin Oncol 2001;20:202a [Abstract].
31. Vasey P. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:202a [Abstract].
32. Kristensen G, Vergote I, Stuart G et al. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/ epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 2002;21:202a [Abstract].
33. Giaccone G, Johnson D, Manegold C et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002;13:2 [Abstract].
34. Johnson D, Herbst R, Giaccone G et al. ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2). Ann Oncol 2002;13:127 [Abstract].
35. Thomas G, Ehlen TG, Gordon AN, Fingert HJ, Nicodemus CF, Schultes BC, Whiteside TL, Berek JS. Adjuvant treatment with monoclonal antibody, OvaRex MAb-B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients (pts) with advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:9 [Abstract].
36. Michael W, Method MW, Gordon A, Finkler N, Fingert H, Nicodemus C, Whiteside T. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex® MAb-B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:21 [Abstract].
37. Epenetos A, Verheijen R. Safety of radioimmunotherapy in International Ovarian Cancer Study. Proc Am Soc Clin Oncol 2000;19:387a [Abstract].
38. de Gramont A, Gangji D, Louvet C et al. Adoptive immunotherapy in ovarian cancer with monocyte derived activated killer cells mixed with anti HER2/ neu + anti Fc gamma RI BISPECIFIC antibody. Proc Am Soc Clin Oncol 2000;19:458a [Abstract].
39. Matei D, Graeber TG, Baldwin RL et al. Gene expression in epithelial ovarian carcinoma. Oncogene 2002;21: 6289-98.
40. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
41. Jazaeri AA, Yee CJ, Sotiriou C et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000.
42. Alaiya AA, Franzen B, Hagman A et al. Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer 2002;98:895-9.